

## **Report from the CMDh meeting held on 18<sup>th</sup> and 19<sup>th</sup> January 2010**

### **Summary of CMDh Activities in 2009**

The CMDh has agreed to publish on the website, for transparency reasons, a summary of the main activities carried out by the CMDh and its sub-groups/working groups in the areas identified as priorities for 2009 in the CMDh work plan. A list of new and revised CMDh documents and questions & answers developed by the CMDh in 2009 is included as an Annex to the document.

### **MRP/DCP statistics in 2009**

Statistics regarding new applications in the MRP and DCP in 2009 according to the 5-level classification will be published on the website.

The statistics will also include information on the referrals to the CMDh, addressing the referrals to the CMDh per type of procedure (MRP vs DCP), per type of product, per therapeutic area, per legal basis, per grounds and per outcome.

### **Implementation of Regulation (EC) No 1234/2008 on variations**

The CMDh has agreed on a template of letter of intent for the submission of a work-sharing procedure. This template will be published on the CMDh website under “Template, variations”.

The CMDh agreed on new Questions & Answers that will be published on the CMDh website to answer general questions in relation with the implementation of Regulation (EC) No 1234/2008.

Applicants are informed that the final version of the application form can be found in the “Notice to Applicants Human, Volume 2C Regulatory Guidelines” published on the EC website ([http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/eudralex/vol-2/index\\_en.htm](http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/eudralex/vol-2/index_en.htm))

### **EU Work-sharing Article 45 of the Paediatric Regulation – Public Assessment Report**

The CMDh has agreed a public assessment report for paediatric studies submitted in accordance with Article 45 of the Paediatric Regulation for tranexamic acid including a recommendation for the text to be included in the SmPC. The Public Assessment Report will be published on the CMDh website, under “Paediatric Regulation, Assessment reports”.

Marketing Authorisation Holders of medicinal products with the same active substance and pharmaceutical form are requested to include this information in their SmPCs (and package leaflets) within 90 days of publication of the public assessment report, in accordance with the Best Practice Guide – Article 45, EU Work-sharing procedure.

### **Revision of the Core SmPC for Hormone Replacement Therapy medicinal products**

The CMDh agreed on a revised Core SmPC for Hormone Replacement Therapy medicinal products. The Core SmPC will be published on the website under “Product Information”.

The CMDh recommends the implementation of the Core SmPC within 18 months with the next regulatory opportunity.

**Propylthiouracil and the risk of serious liver injury**

The CMDh has endorsed the PhVWP report on propylthiouracil and the risk of serious liver injury and recommends the implementation of the PhVWP wording for the SmPC and PL for all products containing propylthiouracil.

The following timetable has been agreed by the CMDh and PhVWP for implementation of agreed SmPC and PL changes:

<b>15 February 2010</b>	Variation applications requested through CMDh
<b>15 March 2010</b>	Variation applications submitted by MA holders
<b>30 April 2010</b>	Variation applications approved by RMS

The PhVWP recommended SmPC and package leaflet wording will be published on the CMDh website, under “Product information, PhVWP recommendations”.

**Valproic Acid the risk of interactions with Carbapenems**

The CMDh has endorsed the PhVWP report on valproic acid and the risk of interaction with carbapenems and recommends the implementation of the PhVWP wording for the SmPC and PL for all products containing valproic acid.

The following timetable has been agreed by the CMDh and PhVWP for implementation of agreed SmPC and PL changes:

<b>1 March 2010</b>	Variation applications requested through CMDh
<b>1 April 2010</b>	Variation applications submitted by MA holders
<b>1 June 2010</b>	Variation applications approved by RMS

The PhVWP recommended SmPC and package leaflet wording will be published on the CMDh website, under “Product information, PhVWP recommendations”.

**CMDh Work plan for 2010**

The CMDh has agreed a work plan for 2010. The work plan will be published on the website, for transparency reasons.

The CMDh identified as new priorities for 2010: the continuous improvement of the Decentralised procedure including validation, clock-stops and national phase of the procedure and the preparation of the CMDh to extended responsibilities foreseen in the new legislative proposals ‘Strategy to better protect Public Health by strengthening and rationalising EU Pharmacovigilance’.

The CMDh maintained as priorities for 2010: an active participation of all CMDh Members in CMDh and Work-sharing activities, the contribution to the successful implementation of the variation Regulation, the elimination of parallel assessment by CMSs, the CMDh contribution to the HMA Taskforce on resources, the implementation of eCTD in MRP and DCP, etc.

A list of documents to be developed and/or revised by the CMDh in 2010 is included as an Annex to the document.

**CMDh Rules of Procedure**

The CMDh has agreed a new version of its rules of procedure. The revised document will be forwarded to the European Commission and to Heads of Medicines Agencies for endorsement.

## **CMDh/European Medicines Agency Sub-Group on Paediatric Regulation**

The CMDh has agreed to publish, for transparency reasons, the CMDh/European Medicines Agency Paediatric Sub-group work plan 2010, including the proposed actions and deadlines to meet the identified work objectives.

Statistics on Member States acting as rapporteurs in paediatric work-sharing procedures will be published on the CMDh website.

## **CMDh meeting with representatives of Interested Parties**

The report from the CMDh meeting on 16 November 2009 with representatives of AESGP, EFPIA and EGA was agreed and will be published on the website under “About CMDh”, “Contact with Representative Organisations” for transparency reasons.

The next CMDh intends to meet again with Interested Parties in June 2010.

## **Information on applications referred to the CMDh in accordance with Article 29(1) of Directive 2001/83/EC, as amended**

Information on the name of the product in the RMS, active substance, pharmaceutical forms, procedure number, CMS, legal basis, grounds for referral to CMDh, Day 60 and outcome of the procedure, for the referrals to the CMDh finalised on 22.12.2009 will be available on the table with information on all applications referred to the CMDh, published under “CMDh-Referrals”.

## **NEW APPLICATIONS**

### **Mutual Recognition Procedure**

The CMDh noted that **40** Mutual Recognition Procedures were finalised during the month of December 2009. **No** Mutual Recognition Procedures were referred to CMDh in this period. **No** Mutual Recognition Procedures referred to CHMP in this period.

The status as of 31<sup>st</sup> December 2009 of procedures under Mutual Recognition is as follows:

Year	New applications finalised <sup>1</sup>	New applications in process	Referred to CMDh	Agreement reached in the CMDh		Withdrawn during CMDh referral	Applications referred to CHMP	
				For procedures referred in			For procedures referred to CMDh in	
				2008	2009		2008	2009
2009	367	68	20	2	12	3	0	3

**26** Mutual Recognition Procedures (regarding **51** products) started in December 2009. The categories of these procedures are as follows:

- **15** abridged applications, including **8** repeat use applications.
- **10** known active substance applications, including **6** repeat use applications.
- **1** line extension applications.

The new procedures started in December 2009 related to **6** full dossier, **14** generic, **4** bibliographic, **1** hybrid and **1** informed consent applications

<sup>1</sup> Due to late database updates cumulative yearly figure differs from the monthly figures. Cumulative yearly figure includes late database updates on finalised procedures not captured in the monthly figures published in press releases. The applications referred to CHMP are included in the ‘new applications finalised.’

## **Report from the CMDh meeting held in January 2010**

25 of these procedures consisted of chemical substance products and 1 procedure consisted of biological (vaccine) products.

These 26 procedures related to prescription-only medicinal products in the reference Member State<sup>2</sup>.

New applications in Mutual Recognition procedure started in December 2009.

<b>Member State</b>	<b>Number of times involved in a procedure as RMS</b>	<b>Number of times involved in a procedure as CMS</b>
Austria	1	8
Belgium		6
Bulgaria		5
Cyprus		1
Czech Republic		7
Denmark	7	12
Estonia		5
Finland	1	4
France	2	9
Germany	1	7
Greece		5
Hungary		7
Iceland		3
Ireland		6
Italy		7
Latvia		5
Lithuania		5
Luxembourg		4
Malta		3
Netherlands	3	6
Norway		6
Poland		8
Portugal	1	6
Romania		7
Slovak Republic		8
Slovenia		6
Spain		6
Sweden	3	7
United Kingdom	7	11

## **Decentralised Procedure**

The CMDh noted that there were 94 Decentralised procedures finalised with a positive outcome and 3 procedures were finalised with a negative outcome. 7 Decentralised procedures were withdrawn after day 120. 1 Decentralised procedure was referred to the CMDh in this period. No Decentralised procedure was referred to the CHMP in this period.

---

<sup>2</sup> In this category products are classified as prescription-only or Non-prescription (OTC) products when the RMS has approved them accordingly, although the legal status is not part of the Mutual Recognition Procedure.

**Report from the CMDh meeting held in January 2010**

The status as of 31<sup>st</sup> December 2009 of procedures under Decentralised Procedure is as follows:

Year	New applications finalised <sup>3</sup>	New applications withdrawn (After day 120)	New applications in process	Referred to CMDh	Agreement reached in the CMDh		Withdrawn during CMDh referral	Referred to CHMP	
					For procedures referred in 2008	2009		For procedures referred to CMDh in 2008	2009
2009	1213	28	1685	19	8	10	1	1	7

**142** Decentralised Procedures (regarding **332** products) started in December 2009. The categories of these procedures are as follows:

- **133** abridged applications, including **41** multiple applications.
- **5** known active substance applications.
- **3** line extension applications.
- **1** new active substance application.

The new Decentralised procedures started in December 2009 related to **121** generic, **3** full dossier, **2** fixed combination, **1** bibliographic and **15** hybrid.

**141** of these procedures consisted of chemical substance applications, **1** procedure consisted of herbal product.

**137** of these procedures related to prescription-only medicinal products and **5** procedures related to non-prescription medicinal products in the reference Member State<sup>4</sup>.

New applications in Decentralised procedure started in December 2009.

Member State	Number of times involved in a procedure as RMS	Number of times involved in a procedure as CMS
Austria	5	38
Belgium		21
Bulgaria		25
Cyprus		7
Czech Republic	3	45
Denmark	14	40
Estonia		16
Finland		26
France	4	42
Germany	25	75
Greece		23
Hungary	1	42
Iceland		3
Ireland		22
Italy	6	55
Latvia		17
Lithuania		22
Luxembourg		14
Malta		6
Netherlands	37	59
Norway		22
Poland		46
Portugal	10	43
Romania		26

<sup>3</sup> Due to late database updates cumulative yearly figure differs from the monthly figures. Cumulative yearly figure includes late database updates on finalised procedures not captured in the monthly figures published in press releases. This cumulative figure includes positive and negative procedures as well as those referred to CHMP.

<sup>4</sup> In this category products are classified as prescription-only or Non-prescription (OTC) products as applied for in the RMS, although the legal status is not part of the Decentralised Procedure.

**Report from the CMDh meeting held in January 2010**

Member State	Number of times involved in a procedure as RMS	Number of times involved in a procedure as CMS
Slovak Republic	6	45
Slovenia		14
Spain	1	48
Sweden	4	31
United Kingdom	26	57

**VARIATIONS AND RENEWALS**

**Mutual Recognition and Decentralised Procedures**

The CMDh noted that **632** type IA variations, **284** type IB variations and **265** type II variations were finalised during the month of December 2009. **38** renewals were finalised in this period. There was **no** procedure referred to the CHMP in this period.

The status as of 31<sup>st</sup> December 2009 of variations and renewals under Mutual Recognition is as follows:

Year	Procedures from Type IA variations finalised	Procedures from Type IB variations finalised	Procedures from Type II variations finalised	Renewals finalised	Applications referred to CHMP
2009	7019	3627	3007	550	6

YEARS	MRP NEW APPLICATIONS FINALISED	DCP NEW APPLICATIONS FINALISED	TYPE I VARIATIONS FINALISED	TYPE IA VARIATIONS FINALISED	TYPE IB VARIATIONS FINALISED	TYPE II VARIATIONS FINALISED	MRP/DCP REFERRED TO CMDh*	ARBITRATIONS REFERRED TO CHMP
1995	10		16			17		1 N.A.
1996	84		49			73		1 N.A. and 1 variation
1997	146		101			163		1 N.A. and 1 variation
1998	182		339			222		1 N.A. and 4 variations
1999	228		671			301		2 N.A. and 2 variations
2000	306		1007			320		3 N.A. and 2 variations
2001	443		1487			474		1 N.A. and 3 variations
2002	420		2104			527		2 N.A. and 7 variations
2003	529		2473	230	94	754		5 N.A. and 3 variations
2004	760		43	3240	1998	1083		9 N.A.
2005	954		N/A	4044	1944	1509	10 N.A.	2 N.A. and 7 variations
2006	535	57	N/A	4524	2209	1916	105 N.A.	22 N.A.
2007	441	392	N/A	5640	2298	2167	69 N.A.	22 N.A. and 8 variations
2008	411	734	N/A	6275	2590	2642	82 N.A.	19 N.A.
2009	378	1304	N/A	7019	3627	3007	39 N.A.	11 N.A. and 6 variations
1995-2009	5827	2487	8290 N/A	30972	14760	15175	305 N.A.	102 N.A. and 44 variations

\*including referrals on renewals

**Report from the CMDh meeting held in January 2010**

**All documents mentioned in this press release can be found at the CMDh website under the heading *Press Releases*.**

*Information on the above mentioned issues can be obtained from the chair of the CMDh or from the CMDh Secretariat:*

*Mrs. Truus Janse-de Hoog  
College ter Beoordeling van Geneesmiddelen  
Kalvermarkt 53  
NL – 2500 Den Haag, The Netherlands*

*Phone: + 31 70 356 74 08  
Fax: + 31 70 356 75 15  
E-mail: [gm.janse@cbg-meb.nl](mailto:gm.janse@cbg-meb.nl)*

*CMDh Secretariat*

*E-mail: [H-CMDhSecretariat@ema.europa.eu](mailto:H-CMDhSecretariat@ema.europa.eu)*

*Or you could visit the **CMDh website** at:*

**<http://www.hma.eu/cmdh.html>**